Skip to content
Dishman Carbogen Amcis logo

Dishman Carbogen Amcis

DCAL NSE
₹150.34 up 1.48 (0.99%)
Market Cap
₹2,357 Cr
P/E
145.96

Dishman Carbogen Amcis (DCAL) share price was ₹148.86 at the 28 Oct 2026 close; market capitalisation ₹2,334 Cr; P/E (TTM) 144.52; sector Healthcare. The share price fell 49.6% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 4.3% year on year to ₹677.6 Cr and net profit was −₹58 Cr, against ₹23 Cr a year earlier (compared with Jun 2025). Promoters held 59.32% of Dishman Carbogen Amcis in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 41/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹148.86 −144.14 −49.19% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹2,357 Cr
P/E (TTM)
145.96
EBITDA
₹622 Cr
Return on Equity
1.46%
Return on Capital Employed
2.91%
Debt to Equity
0.46
Book Value
₹425.87
EPS (TTM)
₹1.03
52W High
₹303.00
52W Low
₹128.50

Price-based figures as of 29 Oct 2026, 11:11 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.4035.044,23,819 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,637.5087.472,55,845 Cr15.260.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,596.9072.161,74,851 Cr9.520.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,184.50107.931,18,031 Cr22.270.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,180.6026.271,17,765 Cr4.340.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,341.2034.741,11,947 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.1032.821,10,685 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
Dishman Carbogen Amcis (this company)
₹150.34145.962,357 Cr0.350.00%1.46%2.91%2,951 Cr16 Cr
Median 8 companies₹1,568.2553.601,17,898 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

41 Weak
Overall score

Data confidence 100/100

Category scores

Quality Good 57
Returns, margins, earnings quality 22% weight
Valuation Average 48
Cheap vs sector & own history 24% weight
Growth Poor 12
Sales & profit trajectory 9% weight
Financial Health Poor 24
Solvency, leverage, coverage 9% weight
Momentum Poor 18
Trend strength, vol-adjusted 12% weight
Ownership Weak 41
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Stock is trading at 0.33 times its book value
  • Company has delivered good profit growth of 20.9% CAGR over last 5 years

Weaknesses

5
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 8.93% over past five years.
  • Company has a low return on equity of -0.40% over last 3 years.
  • Company might be capitalizing the interest cost

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

Bearish

Bearish
9
Neutral
6
Bullish
4

Moving Averages

Bearish

Bearish
7
Neutral
0
Bullish
3

Growth Rate

Revenue Growth
9.32% higher than 3Y

change over 1 year

Net Income Growth
—

Cash Flow Change
32.37%

change over 1 year

EBITDA Margin Change
15.88%

change over 1 year Operating margin 9% · Jun 2026

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Dishman Carbogen Amcis Ltd trades at a market cap of Rs 3,078 Cr with a P/E of 31.6x and a P/B of just 0.46x, reflecting a significant discount to book value. The company has shown strong profit growth (20.9% CAGR over 5 years) but continues to struggle with low return on equity (negative 0.40% over 3 years) and has not paid any dividends despite reporting profits.

Bull Case 8
  • Stock trades at 0.46x book value, indicating significant discount to its net asset base
  • Compounded profit growth of 20.9% CAGR over 5 years demonstrates improving profitability trajectory
  • TTM profit growth of 642% signals a sharp turnaround in recent earnings
  • Compounded sales growth of 9% over 5 years shows steady top-line expansion in the CDMO space
  • TTM revenue growth of 8% indicates continued business momentum
  • 3-year compounded profit growth of 140% reflects sustained earnings recovery
  • ROE improved to 2% in the last year from 0% over 3- and 5-year periods, showing early signs of return improvement
  • 3-year stock CAGR of 12% shows the market has partially re-rated the company over the medium term
Bear Case 8
  • 3-year average ROE of negative 0.40% indicates the company has struggled to generate adequate returns on shareholder equity
  • Zero dividend yield despite reporting profits suggests poor capital return policy or cash flow constraints
  • Low interest coverage ratio points to elevated debt-servicing burden relative to operating earnings
  • Possible capitalization of interest costs may be inflating reported asset values and understating true expenses
  • Sales growth of only 8.93% over 5 years is modest for a healthcare/CDMO company in a high-growth market
  • 1-year stock decline of 25% reflects significant negative market sentiment and possible derating
  • P/E of 31.6x is elevated relative to the weak ROE and modest sales growth, creating valuation risk if earnings falter
  • 10-year ROE averaging just 1% suggests structural challenges in generating consistent shareholder value

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

114d ago
Positives 2
  • FY26 profit turnaround Jun 22

    Dishman Carbogen Amcis reported consolidated net profit of ₹97.45 crore for FY26, a significant turnaround from the previous year. Board also approved raising ECB limits to CHF 200 million.

  • Solar plant commissioned in Switzerland Jun 29

    Subsidiary CARBOGEN AMCIS AG commissioned a 1,200 kWp photovoltaic system in Switzerland to boost renewable energy use and reduce operational costs.

Neutral 2
  • Borrowing limit hike approved Jun 19

    Shareholders approved increasing borrowing limits and a loan from promoter Aamanya AG via ECB route at the EGM held on June 19, 2026.

  • ₹18 crore NCD allotment Jun 9

    Dishman allotted 1,800 secured, senior NCDs aggregating ₹18 crore on June 9, 2026, redeemable by December 2027.

TL;DR: Dishman Carbogen Amcis is showing a meaningful earnings turnaround with ₹97.45 crore net profit in FY26 after a loss-making prior year. The company is actively raising debt via NCDs and ECB routes, suggesting ongoing capital needs for operations or expansion. No clear headwinds emerged in recent news, but the reliance on fresh borrowings warrants monitoring. The trend is improving on profitability, and the renewable energy investment signals long-term cost discipline.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
723
587
651
655
524
789
682
716
708
653
720
851
678
Expenses
602
526
610
592
495
642
542
564
567
504
607
688
618
Operating Profit
122
61
41
63
29
147
140
153
141
149
113
163
60
OPM %
17%
10%
6%
10%
6%
19%
21%
21%
20%
23%
16%
19%
9%
Other Income
7
5
6
4
-4
4
8
-4
22
8
7
15
16
Interest
28
27
33
31
32
37
49
42
43
42
46
43
37
Depreciation
70
75
80
85
71
72
72
79
81
84
84
89
91
PBT
29
-36
-66
-49
-78
42
27
28
39
31
-10
46
-51
Tax %
42%
13%
-10%
42%
0%
21%
83%
-56%
39%
-114%
24%
53%
13%
Net Profit
17
-41
-60
-70
-78
33
5
43
23
65
-13
22
-58
EPS (₹)
1.08
-2.61
-3.8
-4.46
-4.95
2.11
0.3
2.75
1.49
4.16
-0.83
1.39
-3.69
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,031
1,714
1,695
2,059
2,044
1,912
2,141
2,413
2,616
2,712
2,932
2,901
Expenses
830
1,261
1,249
1,507
1,540
1,638
1,809
2,081
2,329
2,243
2,366
2,416
Operating Profit
201
452
445
552
503
274
331
332
286
469
566
485
OPM %
20%
26%
26%
27%
25%
14%
15%
14%
11%
17%
19%
17%
Other Income
14
26
46
54
39
16
29
-20
22
4
52
47
Interest
56
49
49
57
62
48
57
86
120
159
174
169
Depreciation
69
214
211
240
283
308
308
281
311
294
339
348
PBT
91
216
231
309
197
-65
-4
-55
-122
19
105
15
Tax %
12%
33%
33%
32%
20%
154%
-524%
-45%
26%
83%
7%
—
Net Profit
80
145
155
210
159
-165
18
-30
-153
3
97
16
EPS (₹)
—
—
9.58
13.03
10.1
-10.53
1.15
-1.9
-9.79
0.21
6.22
1.03
Div. Payout %
0%
0%
0%
2%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
0
32
32
31
31
31
31
31
31
31
Reserves
863
4,814
5,075
5,347
5,684
5,667
5,518
5,778
5,596
5,800
6,646
Borrowings
868
950
1,095
1,042
1,357
1,589
1,830
2,209
2,313
2,389
3,076
Other Liabilities
334
811
967
899
1,121
1,068
1,255
1,421
1,631
1,766
2,158
Total Liabilities
2,081
6,574
7,169
7,321
8,193
8,356
8,634
9,439
9,571
9,987
11,911
Fixed Assets
1,012
4,852
5,066
5,098
5,678
5,698
5,773
6,188
6,724
7,055
8,076
CWIP
307
133
151
175
234
486
780
1,043
646
467
570
Investments
1
40
196
167
191
172
324
249
102
97
91
Other Assets
761
1,550
1,757
1,881
2,091
2,000
1,758
1,959
2,098
2,368
3,174
Total Assets
2,081
6,574
7,169
7,321
8,193
8,356
8,634
9,439
9,571
9,987
11,911
Figures in ₹ Crores

Cash Flow

Particulars Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
203
303
226
282
585
513
355
266
379
371
491
Investing
-231
-107
-297
-169
-442
-380
-619
-494
-225
-192
-245
Financing
25
-137
78
-102
-98
-11
130
250
-22
-102
201
Net Cash Flow
-3
59
7
11
46
122
-133
22
132
77
447
Free Cash Flow
-37
164
22
-26
177
147
-101
-352
76
156
225
CFO/EBITDA
107
92
58
75
131
206
124
90
139
86
88
Figures in ₹ Crores

Ratios

Particulars Mar 2011Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
60
61
96
79
103
80
81
89
68
90
84
Inventory Days
272
473
525
496
462
402
526
568
540
655
910
Days Payable
172
95
201
176
226
132
158
155
149
168
189
Cash Conversion Cycle
160
439
419
399
340
350
449
502
458
577
805
Working Capital Days
-52
35
44
43
-10
-2
-8
-37
-148
-35
-60
ROCE %
—
—
5%
6%
4%
0%
1%
1%
0%
2%
3%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Dishman Carbogen Amcis insights

66 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

DIIs1.66%Promot.59.32%Others4.35%FIIs6.97%Public27.71%As ofSep 2026
8.39% of promoter holding pledged as of Sep 2026

Documents

Frequently Asked Questions about Dishman Carbogen Amcis

What does Dishman Carbogen Amcis Ltd do?
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]
Where is Dishman Carbogen Amcis Ltd (DCAL) listed?
Dishman Carbogen Amcis Ltd trades as DCAL on the NSE and under code 540701 on the BSE.
Which sector does Dishman Carbogen Amcis Ltd belong to?
Dishman Carbogen Amcis Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd has a market capitalisation of ₹2,357 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd trades at a PE ratio of 145.96 as of 29 Oct 2026, on earnings per share of ₹1.03, against a book value of ₹425.87 per share.
What is the 52-week high and low of Dishman Carbogen Amcis Ltd?
Over the last 52 weeks Dishman Carbogen Amcis Ltd has traded between ₹128.5 and ₹303 as of 29 Oct 2026.
What is the Return on Equity (ROE) of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd reported a return on equity of 1.46%. Its debt-to-equity ratio is 0.46.

Company Information

Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]

Website dishmangroup.com
CEO Mr. Arpit Janmejay Vyas
Employees 1,106
Listed 2017-09-21
Face Value ₹ 2
Shares Outstanding 15,67,83,095

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/DCAL.md for Dishman Carbogen Amcis Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month